Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases

References

• Congdon N, O’Colmain B, Klaver CCW, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477–485.
   PubMedGoogle Scholar
• Vision Problems in the U.S. [Website]. [cited 2018 Oct 1]. Available from: www.visionproblemsus.org
   Google Scholar
• Cohen SY, Dubois L, Ayrault S, et al. Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010. Graefes Arch Clin Exp Ophthalmol. 2013;251:2499–2503.
   PubMed Web of Science ®Google Scholar
• Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220–226.
   PubMed Web of Science ®Google Scholar
• Souied E, Nghiem-Buffet S, Leteneux C, et al. Ranibizumab prefilled syringes: benefits of reduced syringe preparation times and less complex preparation procedures. Eur J Ophthalmol. 2015;25:529–534.
   PubMed Web of Science ®Google Scholar
• Pawlina W, Ross MH. Histology. Lww. Philadelphia; 2015.
   Google Scholar
• Peyman GA, Vastine DW, Meisels HI. The experimental and clinical use of intravitreal antibiotics to treat bacterial and fungal endophthalmitis. Doc Ophthalmol. 1975;39:183–201.
   PubMed Web of Science ®Google Scholar
• Avery RL, Luttrull JK. Inventors; US Patent Office, assignee. Intravitreal medicine delivery patent 5,830,173. 1998
   Google Scholar
• Maurice D. Review: practical issues in intravitreal drug delivery. J Ocul Pharmacol Ther. 2001;17:393–401.
   PubMed Web of Science ®Google Scholar
• Feigenbaum A, Kornblüth W. Intravitreal injection of Penicillin in a case of incipient abscess of the vitreous following extracapsular cataract extraction. Perfect cure. Ophthalmologica. 1945;110:300–305.
   PubMed Web of Science ®Google Scholar
• Baum J, Peyman GA, Barza M. Intravitreal administration of antibiotic in the treatment of bacterial endophthalmitis. III. Consensus. Surv Ophthalmol. 1982;26:204–206.
   PubMed Web of Science ®Google Scholar
• Davis JL, Gilger BC, Robinson MR. Novel approaches to ocular drug delivery. Curr Opin Mol Ther. 2004;3:195–205.
   PubMedGoogle Scholar
• Short BG. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol Pathol. 2008;36:49–62.
   PubMed Web of Science ®Google Scholar
• Keren G, Alhalel A, Bartov E, et al. The intravitreal penetration of orally administered ciprofloxacin in humans. Invest Ophthalmol Vis Sci. 1991;32:2388–2392.
   PubMed Web of Science ®Google Scholar
• Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv. 2006;3:275–287.
   PubMedGoogle Scholar
• Gaudana R, Ananthula HK, Parenky A, et al. Ocular drug delivery. Aaps J. 2010;12:348–360.
   PubMed Web of Science ®Google Scholar
• Agrahari V, Agrahari V, Mandal A, et al. How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches. Expert Opin Drug Deliv. 2017;14:1145–1162.
   PubMed Web of Science ®Google Scholar
• del Amo EM, Rimpelä A-K, Heikkinen E, et al. Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 2017;57:134–185.
   PubMed Web of Science ®Google Scholar
• Villegas VM, Aranguren LA, Kovach JL, et al. Current advances in the treatment of neovascular age-related macular degeneration. Expert Opin Drug Deliv. 2017;14:273–282.
   PubMed Web of Science ®Google Scholar
• Maurice DM, Mishima S. Ocular pharmacokinetics. Pharmacology of the Eye. Berlin, Heidelberg: Springer; 1984. p. 19–116.
   Google Scholar
• Edelhauser HF, Rowe-Rendleman CL, Robinson MR, et al. editors. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010;51:5403–5420.
   Web of Science ®Google Scholar
• Aguirre SA, Gukasyan HJ, Younis HS, et al. Safety assessment of formulation vehicles following intravitreal administration in rabbits. Pharm Res. 2018;35:173–182.
   PubMed Web of Science ®Google Scholar
• Rowe-Rendleman CL, Rowe-Rendleman SAD, Kompella B, et al. Drug and gene delivery to the back of the eye: from bench to bedside. Invest Ophthalmol Vis Sci. 2014;55:2714–2730.
   PubMed Web of Science ®Google Scholar
• Bishop PN. Structural macromolecules and supramolecular organisation of the vitreous gel. Prog Retin Eye Res. 2000;19:323–344.
   PubMed Web of Science ®Google Scholar
• Russell SR, Shepherd JD, Hageman GS. Distribution of glycoconjugates in the human retinal internal limiting membrane. Invest Ophthalmol Vis Sci. 1991;32:1986–1995.
   PubMed Web of Science ®Google Scholar
• Kim H, Robinson SB, Csaky KG. Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm Res. 2009;26:329–337.
   PubMed Web of Science ®Google Scholar
• Dalkara D, Kolstad KD, Caporale N, et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther. 2009;17:2096–2102.
   PubMed Web of Science ®Google Scholar
• Thrimawithana TR, Young S, Bunt CR, et al. Drug delivery to the posterior segment of the eye: challenges and opportunities. Drug Deliv Lett. 2011;1:40–44.
   Google Scholar
• Al-Zamil W, Yassin S. Recent developments in age-related macular degeneration: a review. Cia. 2017;Volume 12:1313–1330.
   Google Scholar
• Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015;49:67–81.
   PubMed Web of Science ®Google Scholar
• Cherepanoff S, McMenamin P, Gillies MC, et al. Bruch’s membrane and choroidal macrophages in early and advanced age-related macular degeneration. Br J Ophthalmol. 2010;94:918–925.
   PubMed Web of Science ®Google Scholar
• Klein ML, Ferris III FL, Armstrong J, et al. Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology. 2008;115:1026–1031.
   PubMed Web of Science ®Google Scholar
• van Lookeren Campagne M, LeCouter J, Yaspan BL, et al. Mechanisms of age‐related macular degeneration and therapeutic opportunities. J Pathol. 2014;232:151–164.
   PubMed Web of Science ®Google Scholar
• Dunaief JL, Dentchev T, Ying G-S, et al. The role of apoptosis in age-related macular degeneration. Arch Ophthalmol. 2002;120:1435–1442.
   PubMedGoogle Scholar
• Kwak N, Okamoto N, Wood JM, et al. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:3158–3164.
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–2548.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2009;355:1419–1431.
   Google Scholar
• Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118:1594–1602.
   PubMed Web of Science ®Google Scholar
• Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27:536–544.
   PubMed Web of Science ®Google Scholar
• Sadiq MA, Agarwal A, Soliman MK, et al. Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation. Expert Opin Drug Saf. 2015;14:1147–1156.
   PubMed Web of Science ®Google Scholar
• Novack GD. Ophthalmic drug delivery: development and regulatory considerations. Clin Pharmacol Ther. 2009;85:539–543.
   PubMed Web of Science ®Google Scholar
• Wang J, Jiang A, Joshi M, et al. Drug delivery implants in the treatment of vitreous inflammation. Mediators Inflamm. 2013;2013:7806–7834.
   Web of Science ®Google Scholar
• Wong FY, Tsang K, Lo AY. Delivery of therapeutics to posterior eye segment: cell-encapsulating systems. Neural Regen Res. 2017;12:576–582.
   PubMed Web of Science ®Google Scholar
• Yasin MN, Svirskis D, Seyfoddin A, et al. Implants for drug delivery to the posterior segment of the eye: a focus on stimuli-responsive and tunable release systems. J Control Release. 2014;196:208–221.
   PubMed Web of Science ®Google Scholar
• Lim JI, Niec M, Wong V. One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD. Br J Ophthalmol. 2015;99:618–623.
   PubMed Web of Science ®Google Scholar
• Cardillo JA, Souza-Filho AA, Oliveira AG. Intravitreal Bioerudivel sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulnes for the treatment of diabetic macular edema. Arch Soc Esp Oftalmol. 2006;81:675–682.
   PubMedGoogle Scholar
• Press release FILLY 12 month results FINAL [Internet]. [2]. 2017. Available from: http://apellis.com/pdfs/Press%20Release%20FILLY%2012%20Month%20Results%20FINAL%20FINAL%20170823.pdf
   Google Scholar
• Drolet DW, Green LS, Gold L, et al. Fit for the eye: aptamers in ocular disorders. Nucleic Acid Ther. 2016;26:127–146.
   PubMed Web of Science ®Google Scholar
• Bansal P, Garg S, Sharma Y, et al. Posterior segment drug delivery devices: current and novel therapies in development. J Ocul Pharmacol Ther. 2016;32:135–144.
   PubMed Web of Science ®Google Scholar
• Eleftheriadou M, Vazquez-Alfageme C, Citu CM, et al. Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting. Am J Ophthalmol. 2017;174:160–168.
   PubMedGoogle Scholar
• Wells JA III, Berger BB, Gonzales C, et al. Multicenter phase 1 clinical trial targeting tissue factor for the treatment of neovascular AMD. Invest Ophthalmol Vis Sci. 2012;53:450.
   Google Scholar
• Yeh S, Kurup SK, Wang RC, et al. Suprachoroidal injection of triamcinolone acetonide, CLS-TA, for macular edema due to noninfectious uveitis: a randomized, phase 2 study (DOGWOOD). Retina (Philadelphia, Pa). 2018;1–9.
   Google Scholar
• Santarelli M, Diplotti L, Samassa F, et al. Advances in pharmacotherapy for wet age-related macular degeneration. Expert Opin Pharmacother. 2015;16:1769–1781.
   PubMed Web of Science ®Google Scholar
• Kidron H, del Amo EM, Vellonen K-S, et al. Prediction of the vitreal half-life of small molecular drug-like compounds. Pharm Res. 2012;29:3302–3311.
   PubMed Web of Science ®Google Scholar
• Del Amo EM, Vellonen K-S, Kidron H, et al. Intravitreal clearance and volume of distribution of compounds in rabbits: in silico prediction and pharmacokinetic simulations for drug development. Eur J Pharm Biopharm. 2015;95:215–226.
   PubMed Web of Science ®Google Scholar
• Saunders LJ, Zhu H, Bunce C, et al. Ophthalmic statistics note 5: diagnostic tests—sensitivity and specificity. Br J Ophthalmol. 2015;99:1168–1170.
   PubMed Web of Science ®Google Scholar
• Fauser S, Muether PS. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression. Br J Ophthalmol. 2016;100:1494–1498.
   Google Scholar
• Xu L, Lu T, Tuomi L, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci. 2013;54:1616–1624.
   PubMed Web of Science ®Google Scholar
• Hutton-Smith LA, Gaffney EA, Bryne HM, et al. Theoretical insights into the retinal dynamics of vascular endothelial growth factor in patients treated with ranibizumab, based on an ocular pharmacokinetic/pharmacodynamic model. Mol Pharm. 2018;15:2770–2784.
   PubMed Web of Science ®Google Scholar
• Hutton-Smith LA, Gaffney EA, Byrne HM, et al. Ocular pharmacokinetics of therapeutic antibodies given by intravitreal injection: estimation of retinal permeabilities using a 3-compartment semi-mechanistic model. Mol Pharm. 2017;14:2690–2696.
   PubMedGoogle Scholar
• Pitkanen L, Ranta V-P, Moilanen H, et al. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest Ophthalmol Vis Sci. 2005;46:641–646.
   PubMed Web of Science ®Google Scholar
• Hutton-Smith LA, Gaffney EA, Byrne HM, et al. A mechanistic model of the intravitreal pharmacokinetics of large molecules and the pharmacodynamic suppression of ocular vascular endothelial growth factor levels by ranibizumab in patients with neovascular age-related macular degeneration. Mol Pharm. 2016;13:2941–2950.
   PubMedGoogle Scholar
• Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–185.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang X, Fuh G, et al. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Mol Pharm. 2014;11:3421–3430.
   PubMed Web of Science ®Google Scholar
• Christoforidis JB, Williams MM, Kothandaraman S, et al. Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT. Curr Eye Res. 2012;37:1171–1174.
   PubMed Web of Science ®Google Scholar
• Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol. 2012;96:1157–1158.
   PubMed Web of Science ®Google Scholar
• Katz B, Macugen GM. (Pegaptanib Sodium), a novel ocular therapeutic that targets vascular endothelial growth factor (VEGF). Int Ophthalmol Clin. 2006;46:141–154.
   PubMedGoogle Scholar
• Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118:831–839.
   PubMed Web of Science ®Google Scholar
• Sadda SR, Guymer R, Holz FG, et al. Consensus definition for atrophy associated with age-related macular degeneration on OCT classification of atrophy report 3. Ophthalmology. 2018;125:537–548
   PubMed Web of Science ®Google Scholar
• Gemenetzi M, Patel PJ. A systematic review of the treat and extend treatment regimen with anti-VEGF agents for neovascular age-related macular degeneration. Ophthalmol Ther. 2017;6:79–92.
   PubMed Web of Science ®Google Scholar
• Joseph M, Trinh HM, Cholkar K, et al. Recent perspectives on the delivery of biologics to back of the eye. Expert Opin Drug Deliv. 2017;14:631–645.
   PubMed Web of Science ®Google Scholar
• Mehta H, Tufail A, Daien V, et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018;65:127–146.
   PubMed Web of Science ®Google Scholar
• Shelke NB, Kadam R, Tyagi P, et al. Intravitreal poly(l-lactide) microparticles sustain retinal and choroidal delivery of tg-0054, a hydrophilic drug intended for neovascular diseases. Drug Deliv Transl Res. 2011;1:76–90.
   PubMed Web of Science ®Google Scholar
• Zhang L, Si T, Fischer AJ, et al. Coaxial electrospray of ranibizumab-loaded microparticles for sustained release of anti-vegf therapies. PLoS ONE. 2015;10:e0135608.
   PubMed Web of Science ®Google Scholar
• Ye Z, Ji Y-L, Ma X, et al. Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits. Int J Ophthalmol. 2015;8:653–658.
   PubMed Web of Science ®Google Scholar
• Yandrapu SK, Upadhyay AK, Petrash JM, et al. Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab. Mol Pharm. 2013;10:4676–4686.
   PubMed Web of Science ®Google Scholar
• de Kozak Y, Andrieux K, Villarroya H, et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol. 2004;34:3702–3712.
   PubMed Web of Science ®Google Scholar
• Varshochian R, Riazi-Esfahani M, Jeddi-Tehrani M, et al. Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment. J Biomed Mater Res A. 2015;103:3148–3156.
   PubMed Web of Science ®Google Scholar
• Huu VAN, Luo J, Zhu J, et al. Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye. J Control Release. 2015;200:71–77.
   PubMed Web of Science ®Google Scholar
• Merodio M, Irache JM, Valamanesh F, et al. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials. 2002;23:1587–1594.
   PubMed Web of Science ®Google Scholar
• MaF, NanK, LeeS, etal. Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system. Eur J Pharm Biopharm. 2015;89:271–279.
   PubMed Web of Science ®Google Scholar
• Yu Y, Lau LCM, Lo AC-Y, et al. Injectable chemically crosslinked hydrogel for the controlled release of bevacizumab in vitreous: a 6-month in vivo study. Transl Vis Sci Technol. 2015;4:5.
   PubMed Web of Science ®Google Scholar
• Rauck BM, Friberg TR, Medina Mendez CA, et al. Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo. Invest Ophthalmol Vis Sci. 2014;55:469–476.
   PubMed Web of Science ®Google Scholar
• Hu -C-C, Chaw J-R, Chen C-F, et al. Controlled release bevacizumab in thermoresponsive hydrogel found to inhibit angiogenesis. Biomed Mater Eng. 2014;24:1941–1950.
   PubMed Web of Science ®Google Scholar
• Lovett ML, Wang X, Yucel T, et al. Silk hydrogels for sustained ocular delivery of anti-vascular endothelial growth factor (anti-VEGF) therapeutics. Eur J Pharm Biopharm. 2015;95:271–278.
   PubMed Web of Science ®Google Scholar
• Xie B, Jin L, Luo Z, et al. An injectable thermosensitive polymeric hydrogel for sustained release of Avastin® to treat posterior segment disease. Int J Pharm. 2015;490:375–383.
   PubMed Web of Science ®Google Scholar
• Fishman PH, Peyman GA, Lesar T. Intravitreal liposome-encapsulated gentamicin in a rabbit model. Prolonged therapeutic levels. Invest Ophthalmol Vis Sci. 1986;27:1103–1106.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Velpandian T, Dhingra N, et al. Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes. J Ocul Pharmacol Ther. 2000;16:511–518.
   PubMed Web of Science ®Google Scholar
• Abrishami M, Zarei-Ghanavati S, Soroush D, et al. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina (Philadelphia, Pa). 2009;29:699–703.
   PubMed Web of Science ®Google Scholar
• Lajavardi L, Camelo S, Agnely F, et al. New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis. J Control Release. 2009;139:22–30.
   PubMed Web of Science ®Google Scholar
• El-Samaligy MS, Rojanasakul Y, Charlton JF, et al. Ocular disposition of nanoencapsulated acyclovir and ganciclovir via intravitreal injection in rabbit’s eye. Drug Deliv. 2008;3:93–97.
   Google Scholar
• Kaji H, Nagai N, Nishizawa M, et al. Drug delivery devices for retinal diseases. Adv Drug Deliv Rev. 2018;128:148–157.
   PubMed Web of Science ®Google Scholar
• Study of the efficacy and safety of the ranibizumab port delivery system (RPDS) for sustained delivery of ranibizumab in participants with subfoveal neovascular age-related macular degeneration (AMD) (LADDER) - full text view. ClinicalTrials.gov.
   Google Scholar
• Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Nat Acad Sci. 2011;108:6241–6245.
   PubMed Web of Science ®Google Scholar
• Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Nat Acad Sci. 2006;103:3896–3901.
   PubMed Web of Science ®Google Scholar
• Neurotech. NT-501 ECT [Website]. [cited 2018 Oct 1]. Available from: http://www.neurotechusa.com/cntfrenexus.html
   Google Scholar
• Humayun M, Santos A, Altamirano JC, et al. Implantable micropump for drug delivery in patients with diabetic macular edema. Transl Vis Sci Technol. 2014;3:5.
   PubMed Web of Science ®Google Scholar
• Weiner AL. refillable devices for therapy of ophthalmic diseases. New York: Springer; 2011.
   Google Scholar
• Meng E, Hoang T. MEMS-enabled implantable drug infusion pumps for laboratory animal research, preclinical, and clinical applications. Adv Drug Deliv Rev. 2012;64:1628–1638.
   PubMed Web of Science ®Google Scholar
• Green-Simms AE, Ekdawi NS, Bakri SJ. Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol. 2011;151:329–332.
   PubMed Web of Science ®Google Scholar
• Rodrigues EB, Grumann A, Penha FM, et al. Effect of needle type and injection technique on pain level and vitreal reflux in intravitreal injection. J Ocul Pharmacol Ther. 2011;27:197–203.
   PubMed Web of Science ®Google Scholar
• Henise J, Hearn BR, Ashley GW, et al. Biodegradable tetra-PEG hydrogels as carriers for a releasable drug delivery system. Bioconjug Chem. 2015;26:270–278.
   PubMed Web of Science ®Google Scholar
• Pastor JC, Lopez MI, Saornil MA, et al. Intravitreal silicone and fluorosilicone oils: pathologic findings in rabbit eyes. Acta Ophthalmol (Copenh). 1992;70:651–658.
   PubMed Web of Science ®Google Scholar
• Giordano GG, Chevez-Barrios P, Refojo MF, et al. Biodegradation and tissue reaction to intravitreous biodegradable poly(D,L-lactic-co-glycolic)acid microspheres. Curr Eye Res. 1995;14:761–768.
   PubMed Web of Science ®Google Scholar
• Hida T, Sheta SM, Proia AD, et al. Experimental transvitreal cyanoacrylate retinopexy in a primate model. Am J Ophthalmol. 1987;103:782–789.
   PubMed Web of Science ®Google Scholar
• Adamson P, Wilde T, Dobrzynski E, et al. Single ocular injection of a sustained-release anti-VEGF delivers 6months pharmacokinetics and efficacy in a primate laser CNV model. J Control Release. 2016;244:1–13.
   PubMed Web of Science ®Google Scholar
• Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58:1131–1135.
   PubMed Web of Science ®Google Scholar
• Rajagopal K, Wood J, Tran B, et al. Trehalose limits BSA aggregation in spray‐dried formulations at high temperatures: implications in preparing polymer implants for long‐term protein delivery. J Pharm Sci. 2013;102:2655–2666.
   PubMed Web of Science ®Google Scholar
• Chang DP, Garripelli VK, Rea J, et al. Investigation of fragment antibody stability and its release mechanism from poly(lactide‐co‐glycolide)–triacetin depots for sustained‐release applications. J Pharm Sci. 2015;104:3404–3417.
   PubMed Web of Science ®Google Scholar
• Ocular Therapeutix (OCUL) Presents at 19th Annual BIO CEO & Investor Conference; 2017 Feb 13; New York, NY. [cited 2018 Oct 1]. Available from: http://www.seekingalpha.com
   Google Scholar
• Rau H, Knappe T, Laufer B, et al. Inventors; US Patent Office, assignee. VEGF Neutralizing Prodrugs for the Treatment of Ocular Conditions patent US20150297740. 2013
   Google Scholar
• Carrasquillo KG, Ricker JA, Rigas IK, et al. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci. 2003;44:290–299.
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Ashley G, Lewis AA, et al. The intravitreal pharmacokinetics of fluorophores conjugated to PEGs by noncleavable and self-cleaving linkers in nonhuman primates. Invest Ophthalmol Vis Sci. 2014;55:5254.
   PubMed Web of Science ®Google Scholar
• Bailon P, Won C-Y. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv. 2009;6:1–16.
   PubMed Web of Science ®Google Scholar
• Chapman AP, Antoniw P, Spitali M, et al. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol. 1999;17:780–783.
   PubMed Web of Science ®Google Scholar
• Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev. 2002;54:531–545.
   PubMed Web of Science ®Google Scholar
• Abuchowski A, McCoy JR, Palczuk NC, et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem. 1977;252:3582–3586.
   PubMed Web of Science ®Google Scholar
• Zalipsky S, Gilon C, Zilkha A. Attachment of drugs to polyethylene glycols. Eur Polym J. 1983;19:1177–1183.
   Web of Science ®Google Scholar
• Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst. 1992;9:249–304.
   PubMed Web of Science ®Google Scholar
• Nucci ML, Shorr R, Abuchowski A. The therapeutic value of poly(ethylene glycol)-modified proteins. Adv Drug Deliv Rev. 1991;6:133–151.
   Web of Science ®Google Scholar
• Harris JM, editor. Introduction to biotechnical and biomedical applications of poly (ethylene glycol). In: Poly (ethylene glycol) chemistry. New York: Springer; 1992. p. 1–14.
   Google Scholar
• Grassi M, Bonora GM, Drioli S, et al. Pharmacokinetic analysis of multi PEG-theophylline conjugates. Comput Biol Chem. 2012;40:7–14.
   PubMed Web of Science ®Google Scholar
• Knadler MP, Nguyen T-H, Campanale K, et al. Addition of 20-kDa PEG to insulin lispro alters absorption and decreases clearance in animals. Pharm Res. 2016;33:1–10.
   Web of Science ®Google Scholar
• Shatz W, Hass PE, Mathieu M, et al. Contribution of antibody hydrodynamic size to vitreal clearance revealed through rabbit studies using a species-matched fab. Mol Pharm. 2016;13:2996–3003.
   PubMedGoogle Scholar
• Eyetech Pharmaceuticals I. Pharmacology/Toxicology Review and Evaluation. In: Services DoHaH, editor. 2004. p. 1–114
   Google Scholar
• CHMP. Macugen, INN-Pegaptanib sodium. CHMP, editor. EPAR: OSI Pharmaceuticals. p. 1–39
   Google Scholar
• Drolet DW, Nelson J, Tucker CE, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res. 2000;17:1503–1510.
   PubMed Web of Science ®Google Scholar
• Rudmann DG, Alston JT, Hanson JC, et al. High molecular weight polyethylene glycol cellular distribution and peg-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins. Toxicol Pathol. 2013;41:970–983.
   PubMed Web of Science ®Google Scholar
• Ginn C, Khalili H, Lever R, et al. PEGylation and its impact on the design of new protein-based medicines. Future Medicinal Chemistry. 2014;6:1829–1846.
   Google Scholar
• Turecek PL, Bossard MJ, Schoetens F, et al. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J Pharm Sci. 2016;105:460–475.
   PubMed Web of Science ®Google Scholar
• Ivens IA, Achanzar W, Baumann A, et al. PEGylated Biopharmaceuticals. Toxicol Pathol. 2015;43:959–983.
   PubMedGoogle Scholar
• Hennig R, Veser A, Kirchhof S, et al. Branched polymer-drug conjugates for multivalent blockade of angiotensin II receptors. Mol Pharm. 2015;12:3292–3302.
   PubMedGoogle Scholar
• Altiok EI, Santiago-Ortiz JL, Svedlund FL, et al. Multivalent hyaluronic acid bioconjugates improve sFlt-1 activity in vitro. Biomaterials. 2016;93:95–105.
   PubMed Web of Science ®Google Scholar
• Altiok EI, Browne S, Khuc E, et al. sFlt multivalent conjugates inhibit angiogenesis and improve half-life in vivo. PLoS ONE. 2016;93:1–14.
   Web of Science ®Google Scholar
• Robbie GJ, Criste R, Dall’Acqua WF, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013;57:6147–6153.
   PubMed Web of Science ®Google Scholar
• Yeh P, Landais D, Lemaître M, et al. Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc Nat Acad Sci. 1992;89:1904–1908.
   PubMed Web of Science ®Google Scholar
• O’Connor-Semmes RL, Lin J, Hodge RJ, et al. GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety. Clin Pharmacol Ther. 2014;96:704–712.
   PubMed Web of Science ®Google Scholar
• Krohne TU, Liu Z, Holz FG, et al. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012;154:682–686.
   PubMed Web of Science ®Google Scholar
• Krohne TU, Eter N, Holz FG, et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;146:508–512.
   PubMed Web of Science ®Google Scholar
• Maurice DM. Protein dynamics in the eye studied with labelled proteins. Am J Ophthalmol. 1959;47:361–368.
   PubMed Web of Science ®Google Scholar
• Gadkar K, Pastuskovas CV, Le Couter JE, et al. Design and pharmacokinetic characterization of novel antibody formats for ocular therapeutics. Invest Ophthalmol Vis Sci. 2015;56:5390–5400.
   PubMed Web of Science ®Google Scholar
• Fuchs H, Igney F. Binding to ocular albumin as a half-life extension principle for intravitreally injected drugs: evidence from mechanistic rat and rabbit studies. J Ocul Pharmacol Ther. 2017;33:115–122.
   PubMed Web of Science ®Google Scholar
• Kim B-J, Zhou J, Martin B, et al. Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides. J Pharmacol Exp Ther. 2010;334:682–692.
   PubMed Web of Science ®Google Scholar
• Kokavec J, Min SH, Tan MH, et al. Biochemical analysis of the living human vitreous. Clin Exp Ophthalmol. 2016;44:597–609.
   PubMed Web of Science ®Google Scholar
• Michael IP, Westenskow PD, Hacibekiroglu S, et al. Local acting sticky-trap inhibits vascular endothelial growth factor dependent pathological angiogenesis in the eye. EMBO Mol Med. 2014;6:604–623.
   PubMed Web of Science ®Google Scholar
• Clark SJ, Keenan TDL, Fielder HL, et al. Mapping the differential distribution of glycosaminoglycans in the adult human retina, choroid, and sclera. Invest Ophthalmol Vis Sci. 2011;52:6511–6521.
   PubMed Web of Science ®Google Scholar
• Laurent UBG, Fraser JRE. Turnover of hyaluronate in the aqueous humour and vitreous body of the rabbit. Exp Eye Res. 1983;36:493–503.
   PubMed Web of Science ®Google Scholar
• Bishop PN, Holmes DF, Kadler KE, et al. Age-related changes on the surface of vitreous collagen fibrils. Invest Ophthalmol Vis Sci. 2004;45:1041–1046.
   PubMed Web of Science ®Google Scholar
• Sebag J. The vitreous. New York (NY): Springer Science & Business Media; 2012.
   Google Scholar
• Ghosh J, Roguska M, Nguyen AA, Inventors; US patent office, assignee. Compositions and methods for long acting molecules patent US20160297854. 2016.
   Google Scholar
• Ghosh JG, Nguyen AA, Bigelow CE, et al. Long-acting protein drugs for the treatment of ocular diseases. Nat Commun. 2017;1–10.
   PubMed Web of Science ®Google Scholar
• Making eye health a population health imperative: vision for tomorrow. In: Teutsch SM, McCoy MA, Woodbury RB, Welp A, editors The national academies collection: reports funded by national institutes of health. Washington (DC): National Academies Press (US); 2016;1–23.
   Google Scholar
• Englander M, Chen TC, Paschalis EI, et al. Intravitreal injections at the massachusetts eye and ear infirmary: analysis of treatment indications and postinjection endophthalmitis rates. Br J Ophthalmol. 2013;97:460–465.
   PubMed Web of Science ®Google Scholar
• Patel SR, Berezovsky DE, McCarey BE, et al. Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Invest Ophthalmol Vis Sci. 2012;53:4433–4441.
   PubMed Web of Science ®Google Scholar